Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Vtama (tapinarof) is indicated for the topical treatment of plaque psoriasis in adults.
• This summary is based on the review of five systematic review(s)/meta-analysis(es). 3. 1% tapinarof cream demonstrated superior effectiveness in treating psoriasis compared to placebo with Odds Ratios (OR) of 8.3 (95% CI: 5.5, 13.0) at 4 weeks, 8.3 (95% CI: 5.9, 13.0) at 8 weeks, and 7.3 (95% CI: 5.1, 11.0) at 12 weeks. It was also superior to calcipotriol, though specific OR values were not provided. ^[1-5]
• Benvitimod significantly improved multiple psoriasis outcomes compared to placebo, including a Physician Global Assessment (PGA) score of 0 or 1 (Relative Risk [RR] = 6.53, 95% CI: 4.39, 9.71), PASI 75 (RR = 4.34, 95% CI: 2.96, 6.36), and PASI 90 (RR = 8.83, 95% CI: 5.22, 14.95).
• For atopic dermatitis, tapinarof, crisaborole, and ruxolitinib led to statistically significant improvements in disease severity scores, while ARQ-151 cream achieved statistical significance in secondary endpoints, such as vIGA-AD and EASI-75, but not in the primary endpoint.
• The incidence of adverse events was higher for 1% tapinarof cream compared to placebo (OR = 3.3, 95% CI: 2.6, 4.3) and calcipotriol; no serious systemic adverse events were reported.
• Benvitimod showed a higher incidence of adverse events compared to placebo (RR = 1.98, 95% CI: 1.73, 2.27); the risk for serious adverse events was non-significant.
• Tapinarof, crisaborole, ARQ-151 cream, and ruxolitinib were well-tolerated by study participants, with no serious safety concerns highlighted.
• There is no population types or subgroups information available in the reviewed studies.